Rallybio (NASDAQ:RLYB) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Rallybio (NASDAQ:RLYB) released its earnings results on Monday. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.01, FiscalAI reports. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.10 million. Rallybio had a negative return on equity of 65.23% and a negative net margin of 2,102.37%.

Rallybio Trading Down 0.9%

NASDAQ:RLYB traded down $0.09 during midday trading on Monday, reaching $9.41. The company had a trading volume of 123,701 shares, compared to its average volume of 140,824. Rallybio has a 12-month low of $1.76 and a 12-month high of $11.49. The firm has a market capitalization of $49.71 million, a price-to-earnings ratio of -3.68 and a beta of -1.13. The stock’s fifty day simple moving average is $6.30 and its 200-day simple moving average is $5.47.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a research note on Monday, December 29th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Rallybio has an average rating of “Reduce” and an average target price of $40.00.

Hedge Funds Weigh In On Rallybio

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its stake in shares of Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after buying an additional 120,892 shares during the period. Citadel Advisors LLC increased its stake in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares during the period. Geode Capital Management LLC raised its holdings in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after acquiring an additional 2,996 shares in the last quarter. Susquehanna International Group LLP raised its holdings in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares in the last quarter. Finally, XTX Topco Ltd lifted its stake in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares during the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.